Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity

Transplantation

Volumn 79, Issue 4, 2005, Pages 419-426

  Shihab, Fuad S ^a   Bennett, William M ^b   Yi, Hong ^a   Andoh, Takeshi F ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Legacy Solid Organ and Cellular Transplantation Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLOSPORIN A; DNA NUCLEOTIDYLEXOTRANSFERASE; FAS LIGAND; MESSENGER RNA; PIRFENIDONE; PROTEIN BCL XL; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EPITHELIUM CELL; FIBROSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATOR GENE; STAINING;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CASPASES; CYCLOSPORINE; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; GENES, P53; IN SITU NICK-END LABELING; KIDNEY; MALE; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 14044262258     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000151721.99418.48     Document Type: Article

References (39)

1. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089.
2. Shihab FS. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 1996; 16: 536.
3. Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141.
4. Shihab FS, Bennett WM, Tanner AM, et al. Angiotensin II blockade decreases TGF-β1 and matrix proteins in chronic cyclosporine nephropathy. Kidney Int 1997; 52: 660.
5. Shihab FS, Yi H, Bennett WM, et al. Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58: 1174.
6. Shihab FS, Bennett WM, Yi H, et al. Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2: 111.
7. Shihab FS, Andoh TF, Tanner AM, et al. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56: 2147.
8. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355.
9. Saikumar P, Venkatachalam MA. Role of apoptosis in hypoxic/ischemic damage in the kidney. Semin Nephrol 2003; 23: 511.
10. Kashihara N, Sugiyama H, Makino H. Implication of apoptosis in progression of renal diseases. Contrib Nephrol 2003; 139: 156.
11. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002; 11: 301.
12. Savill J. Apoptosis and the kidney. J Am Soc Nephrol 1994; 5: 12.
13. Yang CW, Faulkner GR, Wahba IM, et al. Expression of apoptosis-related genes in chronic cyclosporine nephrotoxicity in mice. Am J Transplant 2002; 2: 391.
14. Ortiz A, Lorz C, Catalan M, et al. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int 1998; 68: S25.
15. Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin induced lung fibrosis in hamsters. J Lab Clin Med 1995; 125: 779.
16. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159: 1061.
17. Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 2002; 37: 584.
18. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002; 135: 961.
19. Fukagawa M, Noda M, Shimizu T, et al. Chronic progressive interstitial fibrosis in renal disease - are there novel pharmacologic approaches? Nephrol Dial Transplant 1999; 14: 2793.
20. Shimizu F, Fukagawa M, Yamauchi S, et al. Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions. Nephrol 1997; 3: 315.
21. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 1997; 52: S239.
22. Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99.
23. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998; 83: 219.
24. Dosanjh AK, Wan B, Throndset W, et al. Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proc 1998; 30: 1910.
25. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) downregulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 72.
26. Iyer SN, Margolin SB, Hyde DM, et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three dose bleomycin hamster model. Exp Lung Res 1998; 24: 119.
27. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53: 897.
28. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA damaging agents and growth arrest. Mol Cell Biol 1993; 13: 4242.
29. Lowe SW, Scmitt EM, Smith SW, et al. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362: 847.
30. Morrissey JJ, Ishidoya S, McCracken R, et al. The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int 1996; 54: S83.
31. Sandau K, Pfeilschifter J, Brüne B. Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kidney Int 1997; 52: 378.
32. Healy E, Dempsey M, Lally C, et al. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in renal proximal tubular cell line. Kidney Int 1998; 54: 1955.
33. Nogae S, Miyazaki M, Kobayashi N, et al. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. J Am Soc Nephrol 1998; 9: 620.
34. Hockenbery DM, Oltavi ZN, Yin X-M, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241.
35. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1992; 348: 384.
36. Tsuchiya H, Kaibori M, Yanagida H, et al. Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 2004; 40: 94.
37. Oberhammer FA, Pavelka M, Sharma S, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci 1992; 89: 5408.
38. Cigola E, Kajstura J, Li B, et al. Angiotensin II activates programmed cell death in vitro. Exp Cell Res 1997; 231: 363.
39. 2+ elevation and cyclosporine A synergistically induce TGF-β1-mediated apoptosis in lymphocytes. J Immunol 1997; 158: 2527.